Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2014

26 - 30 Sep 2014
IFEMA – Feria de Madrid, Madrid, Spain
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: W...
Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
11 Feb 2015
mRCC: Are we doing all we can to manage adverse events?
Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
11 Feb 2015
mRCC: Real-world experience: achieving efficacy beyond clinical trials
Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA
mRCC: Real-world experience: achieving efficacy beyond clinical trials ( Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA )
11 Feb 2015
mRCC: Understanding the patient's perspective
Dr David Cella - Northwestern University, Chicago, USA
mRCC: Understanding the patient's perspective ( Dr David Cella - Northwestern University, Chicago, USA )
11 Feb 2015
mRCC: Panel discussion
Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella
mRCC: Panel discussion ( Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella )
11 Feb 2015
mRCC: Closing remarks
Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
mRCC: Closing remarks ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
11 Feb 2015
Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity ...
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium
Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )
29 Jan 2015
Optimizing survival in advanced prostate cancer: Welcome and introduction
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium
Optimizing survival in advanced prostate cancer: Welcome and introduction ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )
29 Jan 2015
Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to op...
Prof Karim Fizazi - Institut Gustave Roussy, Paris, France
Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival ( Prof Karim Fizazi - Institut Gustave Roussy, Paris, France )
29 Jan 2015
Optimizing survival in advanced prostate cancer: CHAARTED: What are the implica...
Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA
Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future? ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )
29 Jan 2015
Optimizing survival in advanced prostate cancer: Learnings from real life practi...
Prof Bertrand Tombal - Saint-Luc Hospital, Brussels, Belgium
Optimizing survival in advanced prostate cancer: Learnings from real life practice ( Prof Bertrand Tombal - Saint-Luc Hospital, Brussels, Belgium )
29 Jan 2015
Optimizing Survival in Advanced Prostate Cancer: Conclusion
Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium
Optimizing Survival in Advanced Prostate Cancer: Conclusion ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )
29 Jan 2015
Overall survival update from the BREAK-3 study
Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany
Overall survival update from the BREAK-3 study ( Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany )
4 Dec 2014
Early events found to trigger lung cancer twenty years before diagnosis
Prof Charles Swanton - Cancer Research UK's London Research Institute, London, U...
Early events found to trigger lung cancer twenty years before diagnosis ( Prof Charles Swanton - Cancer Research UK's London Research Institute, London, UK )
14 Nov 2014
Cancer Core Europe: Introduction
Prof Alexander Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Sche...
Cancer Core Europe: Introduction ( Prof Alexander Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens, Prof Alejandro Piris, Prof Thorston Zenz )
20 Oct 2014
Cancer Core Europe: National Center for Tumor Diseases
Prof Thorston Zenz - National Center for Tumor Diseases, Heidelberg, Germany
Cancer Core Europe: National Center for Tumor Diseases ( Prof Thorston Zenz - National Center for Tumor Diseases, Heidelberg, Germany )
20 Oct 2014
Cancer Core Europe: Vall d'Hebron Institute of Oncology
Prof Alejandro Piris - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Cancer Core Europe: Vall d'Hebron Institute of Oncology ( Prof Alejandro Piris - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
20 Oct 2014
Cancer Core Europe: Cancer Research UK Cambridge Institute
Prof Carlos Caldas - Cancer Research UK Cambridge Institute, Cambridge, UK
Cancer Core Europe: Cancer Research UK Cambridge Institute ( Prof Carlos Caldas - Cancer Research UK Cambridge Institute, Cambridge, UK )
20 Oct 2014
Cancer Core Europe: Karolinska Institute
Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden
Cancer Core Europe: Karolinska Institute ( Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden )
20 Oct 2014
Cancer Core Europe: Institut Gustave Roussy
Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France
Cancer Core Europe: Institut Gustave Roussy ( Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France )
20 Oct 2014
Cancer Core Europe: Netherlands Cancer Institute
Prof Jan Schellens - Netherlands Cancer Institute, Amsterdam, Netherlands
Cancer Core Europe: Netherlands Cancer Institute ( Prof Jan Schellens - Netherlands Cancer Institute, Amsterdam, Netherlands )
20 Oct 2014
Cancer Core Europe: Questions and answers
Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens,...
Cancer Core Europe: Questions and answers ( Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens, Prof Piris, Prof Lenz )
20 Oct 2014
Cancer Core Europe: Consortium to address the care-research continuum challenge
Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg
Cancer Core Europe: Consortium to address the care-research continuum challenge ( Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg )
17 Oct 2014
ESMO 2014: News Roundup
ecancer News Team
ESMO 2014: News Roundup ( ecancer News Team )
16 Oct 2014
ESMO 2014 Editor's roundup
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ESMO 2014 Editor's roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
8 Oct 2014
Ipilimumab extends relapse-free survival in resectable melanoma
Prof Alexander Eggermont - Gustave Roussy, Villejuif, France
Ipilimumab extends relapse-free survival in resectable melanoma ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )
2 Oct 2014
Prognostic biomarkers will detect lung cancer at earlier stages
Prof Giulia Veronesi - European Institute of Oncology, Milan, Italy
Prognostic biomarkers will detect lung cancer at earlier stages ( Prof Giulia Veronesi - European Institute of Oncology, Milan, Italy )
2 Oct 2014
vandetanib improves PFS in thyroid cancer
Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain
vandetanib improves PFS in thyroid cancer ( Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain )
2 Oct 2014
E-hospital: Fully coordinated cancer care and research in Europe
Prof Alexander Eggermont - Gustave Roussy, Villejuif, France
E-hospital: Fully coordinated cancer care and research in Europe ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )
2 Oct 2014
ESMO Highlights: Breast cancer
Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
ESMO Highlights: Breast cancer ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
2 Oct 2014
Combination of capecitabine and bevacizumab improves progression-free survival i...
Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France
Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer ( Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France )
2 Oct 2014
Research shows chemotherapy has no negative effects on babies in utero
Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium
Research shows chemotherapy has no negative effects on babies in utero ( Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium )
1 Oct 2014
Importance of gynaecological surgeons and multidisciplinary strategies in advanc...
Dr Lucas Minig - Valencia Institute of Oncology, Valencia, Spain
Importance of gynaecological surgeons and multidisciplinary strategies in advanced ovarian cancer ( Dr Lucas Minig - Valencia Institute of Oncology, Valencia, Spain )
1 Oct 2014
Raising awareness about head and neck cancer through the Make Sense campaign
Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille, Fr...
Raising awareness about head and neck cancer through the Make Sense campaign ( Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille, France )
1 Oct 2014
Cancer care in developing countries
Prof Ian Magrath - International Network for Cancer Treatment and Research, Brus...
Cancer care in developing countries ( Prof Ian Magrath - International Network for Cancer Treatment and Research, Brussels, Belgium )
1 Oct 2014
Treatment options in castration-resistant prostate cancer: Expert discussion
Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane O...
Treatment options in castration-resistant prostate cancer: Expert discussion ( Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard )
29 Sep 2014
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
Dr Caroline Robert - Gustave Roussy, Villejuif, France
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014
Nivolumab potentially superior to standard chemo in advanced melanoma
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014
Targeted therapy for iodine-refractory thyroid cancer
Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan
Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )
29 Sep 2014
Young oncologists bridging the gap between translational and clinical cancer res...
Prof Joan Seoane - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Young oncologists bridging the gap between translational and clinical cancer research ( Prof Joan Seoane - Vall d’Hebron Institute of Oncology, Barcelona, Spain )
29 Sep 2014
Questions raised about the future of lung cancer vaccination?
Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium
Questions raised about the future of lung cancer vaccination? ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )
29 Sep 2014
Cancer care as a human right in low-income countries
Prof Eduardo Cazap - SLACOM, Buenos Aires, Argentina
Cancer care as a human right in low-income countries ( Prof Eduardo Cazap - SLACOM, Buenos Aires, Argentina )
29 Sep 2014
PD-L1 protein a possible immunotherapy target in mesothelioma
Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland
PD-L1 protein a possible immunotherapy target in mesothelioma ( Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland )
29 Sep 2014
Improved response rate and survival with dabrafenib plus trametinib versus vemur...
Dr Caroline Robert - Gustave Roussy, Villejuif, France
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )
29 Sep 2014
Vemurafenib plus cobimetinib achieves significant progression-free survival in m...
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2014
Nivolumab shows signs of superior response rate compared to standard chemo in ad...
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )
29 Sep 2014
EORTC and the management of clinical trial data
Anastassia Negrouk - European Organisation for Research and Treatment of Cancer,...
EORTC and the management of clinical trial data ( Anastassia Negrouk - European Organisation for Research and Treatment of Cancer, Brussels, Belgium and Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
29 Sep 2014
Improvements in progression free survival for patients with metastatic head and ...
Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium
Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )
28 Sep 2014
Financial impact of a cancer diagnosis
Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium
Financial impact of a cancer diagnosis ( Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium )
28 Sep 2014
Combining cobimetinib and vemurafenib improves progression-free survival in adva...
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Sep 2014
Molecular targeting in cancer and the impact on personalised medicine
Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research...
Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )
28 Sep 2014
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for ...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
Cediranib and chemo combo improves PFS for metastatic cervical cancer
Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK
Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )
28 Sep 2014
Phase III trial results raise questions about the future of lung cancer vaccinat...
Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium
Phase III trial results raise questions about the future of lung cancer vaccination ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )
28 Sep 2014
Little benefit for gefitinib-resistant lung cancer when continuing the drug with...
Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China
Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy ( Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China )
28 Sep 2014
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for ...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
Adding cediranib to chemo improves PFS for metastatic cervical cancer
Dr Paul Symonds - University Hospital of Leicester, Leicester, UK
Adding cediranib to chemo improves PFS for metastatic cervical cancer ( Dr Paul Symonds - University Hospital of Leicester, Leicester, UK )
28 Sep 2014
Helping cancer patients make sense of risk
Prof Rocio Garcia-Retamero - University of Granada, Granada, Spain
Helping cancer patients make sense of risk ( Prof Rocio Garcia-Retamero - University of Granada, Granada, Spain )
28 Sep 2014
New horizons in prostate cancer: The final results of the COU-302 abiraterone st...
Prof Charles Ryan and Prof Gordon McVie
New horizons in prostate cancer: The final results of the COU-302 abiraterone study ( Prof Charles Ryan and Prof Gordon McVie )
28 Sep 2014
Reducing nausea and vomiting associated with cisplatin-based chemotherapy with r...
Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Afr...
Reducing nausea and vomiting associated with cisplatin-based chemotherapy with rolapitant ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )
27 Sep 2014
Rare cancers and the difficulties in making clinical decisions
Dr Paolo Casali - National Tumour Institute, Milan, Italy
Rare cancers and the difficulties in making clinical decisions ( Dr Paolo Casali - National Tumour Institute, Milan, Italy )
27 Sep 2014
Anamorelin improves appetite and body mass in non-small cell lung cancer with ca...
Dr David Currow - Flinders University, Adelaide, Australia
Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Dr David Currow - Flinders University, Adelaide, Australia )
27 Sep 2014
Study shows chemotherapy and radiotherapy are safe for babies in utero
Prof Frederic Amant - University Hospital Leuven
Study shows chemotherapy and radiotherapy are safe for babies in utero ( Prof Frederic Amant - University Hospital Leuven )
27 Sep 2014
Rolapitant reduces nausea and vomiting associated with cisplatin-based chemother...
Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Afr...
Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )
27 Sep 2014
New drug anamorelin shows improvement in appetite and body mass in non-small cel...
Prof David Currow - Flinders University, Adelaide, Australia
New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Prof David Currow - Flinders University, Adelaide, Australia )
27 Sep 2014
Second-line afatinib significantly improves PFS in metastatic head and neck canc...
Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium
Second-line afatinib significantly improves PFS in metastatic head and neck cancer ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )
27 Sep 2014